Impact of Anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: Analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty complications (CADILLAC) trial

We sought to investigate the impact of anemia in patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI). The prognostic importance of anemia on primary PCI outcomes is unknown. In the Controlled Abciximab and Device Investigation to Lower Late Ang...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American College of Cardiology 2004-08, Vol.44 (3), p.547-553
Hauptverfasser: NIKOLSKY, Eugenia, AYMONG, Eve D, STUCKEY, Thomas, TURCO, Mark, COHEN, David A, NEGOITA, Manuela, LANSKY, Alexandra J, STONE, Gregg W, HALKIN, Amir, GRINES, Cindy L, COX, David A, GARCIA, Eulogio, MEHRAN, Roxana, TCHENG, James E, GRIFFIN, John J, GUAGLIUMI, Giulio
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We sought to investigate the impact of anemia in patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI). The prognostic importance of anemia on primary PCI outcomes is unknown. In the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial, 2,082 patients of any age with AMI within 12 h onset undergoing primary PCI were randomized to balloon angioplasty versus stenting, each +/- abciximab. Outcomes were stratified by the presence of anemia at baseline, as defined by World Health Organization criteria (hematocrit
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2004.03.080